In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research.

Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain.

Guests:

Dr. Hidehito Horinouchi

Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo

General Secretary, Japan Clinical Oncology Group

Dr. Noemi Reguart

Clinical Professor at the University of Barcelona

Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain

WCLC 2025 Co-Chair

Dr. Jacob Sands

Assistant Professor of Medicine, Harvard Medical School

Lowe Cancer Center for Thoracic Oncology

Dana Farber Cancer Institute